NCT03691818 is a Phase 2 clinical trial of X0002 Spray in KNEE OSTEOARTHRITIS, sponsored by Tianjin XinChen-Techfields Pharma Co., LTD..

Who is sponsoring NCT03691818?

NCT03691818 is sponsored by Tianjin XinChen-Techfields Pharma Co., LTD..

What drugs are being tested in NCT03691818?

Interventions in NCT03691818: X0002 Spray, Ibuprofen Tablet, Ibuprofen Placebo Tab, X0002 Placebo Spray.

What condition does NCT03691818 study?

NCT03691818 studies KNEE OSTEOARTHRITIS.

Is NCT03691818 still recruiting?

NCT03691818 is currently completed. Last updated 13 January 2020.

Last reviewed 2020-01-13 · How we verify

NCT03691818

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

Completed Phase 2 Last updated 13 January 2020

What this trial tests

Phase 2 trial testing X0002 Spray in KNEE OSTEOARTHRITIS in 353 participants. Completed in 21 October 2019.

Timeline

16 July 2018

Primary endpoint
21 October 2019

21 October 2019

Quick facts

Lead sponsor	Tianjin XinChen-Techfields Pharma Co., LTD.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	353
Start date	16 July 2018
Primary completion	21 October 2019
Estimated completion	21 October 2019
Sites	1 location across China

Drugs / interventions tested

X0002 Spray
Ibuprofen Tablet
Ibuprofen Placebo Tab — full drug profile →
X0002 Placebo Spray

Conditions studied

KNEE OSTEOARTHRITIS — all drugs for KNEE OSTEOARTHRITIS →

Sponsor

Tianjin XinChen-Techfields Pharma Co., LTD. — full company profile →

Who can join

Adults 40 to 75, any sex, with KNEE OSTEOARTHRITIS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized, double-blind clinical trial in a Chinese population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments.
Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. · · 2021 · cited 16× · PMID 36474768 · DOI 10.1016/j.ocarto.2021.100212

Verify or expand the search:

Other trials of X0002 Spray

Trials testing the same drug.

NCT05324163 — Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03691818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin XinChen-Techfields Pharma Co., LTD.
Last refreshed: 13 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03691818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing